Cancer: RANKL inhibition—a new weapon against breast cancer?

Comment

Linda Koch. Nat Rev Endocrinol. 2011 Jan.

. 2011 Jan;7(1):2.

doi: 10.1038/nrendo.2010.202.

No abstract available

Comment on

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.
Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM. Schramek D, et al. Nature. 2010 Nov 4;468(7320):98-102. doi: 10.1038/nature09387. Epub 2010 Sep 29. Nature. 2010. PMID: 20881962 Free PMC article.
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.
Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC. Gonzalez-Suarez E, et al. Nature. 2010 Nov 4;468(7320):103-7. doi: 10.1038/nature09495. Epub 2010 Sep 29. Nature. 2010. PMID: 20881963